JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

15.77 0.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.25

Максимум

16.15

Ключови измерители
By Trading Economics
Приходи	35M 9.5M
Продажби	35M 94M
Марж на печалбата	10.158
Служители	619
EBITDA	35M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+32.28% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	167M 2.8B
Предишно отваряне	15
Предишно затваряне	15.77

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.02.2026 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Technical Correction -- Market Talk

9.02.2026 г., 23:14 ч. UTC

Пазарно говорене

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9.02.2026 г., 22:29 ч. UTC

Пазарно говорене

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9.02.2026 г., 22:19 ч. UTC

Пазарно говорене

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9.02.2026 г., 22:01 ч. UTC

Печалби

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9.02.2026 г., 21:58 ч. UTC

Печалби

Friedman Industries 3Q Sales $168M >FRD

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 21:48 ч. UTC

Печалби

Friedman Industries 3Q EPS 43c >FRD

9.02.2026 г., 21:17 ч. UTC

Печалби

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9.02.2026 г., 21:13 ч. UTC

Пазарно говорене

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9.02.2026 г., 21:04 ч. UTC

Печалби

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9.02.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9.02.2026 г., 20:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9.02.2026 г., 19:42 ч. UTC

Пазарно говорене

Japan's Yield Curve Expected to Flatten -- Market Talk

9.02.2026 г., 19:31 ч. UTC

Пазарно говорене

Nike Seen Regaining Relevance With Consumers -- Market Talk

9.02.2026 г., 19:27 ч. UTC

Пазарно говорене

Gold Climbs Back Over $5,000/oz -- Market Talk

9.02.2026 г., 19:05 ч. UTC

Пазарно говорене

Nike Returns to List of Hottest Brands -- Market Talk

9.02.2026 г., 18:19 ч. UTC

Пазарно говорене

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9.02.2026 г., 17:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9.02.2026 г., 17:31 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 17:17 ч. UTC

Пазарно говорене

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9.02.2026 г., 17:16 ч. UTC

Печалби

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

32.28% нагоре

12-месечна прогноза

Среден 20.86 USD 32.28%

Висок 22 USD

Нисък 20 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.